Study of Targeted Therapy for HER2Positive Metastatic Breast Cancer

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=CO0l0ib53GI

Ian E. Krop, MD, PhD, provides an overview of a study comparing HER2-targeted antibody-drug conjugate DS-8201a (trastuzumab deruxtecan) with the current standard of care in people with HER2-positive metastatic breast cancer previously treated with T-DM1. • Dana-Farber Cancer Institute offers the largest number of clinical trials for metastatic breast cancer in the country through our Embrace program. For more information about clinical trials for breast cancer, please visit http://dfcibreastclinicaltrials.org/. • For more information about Embrace, please visit https://www.dana-farber.org/metastati...

#############################